POS1037 Effect Of Guselkumab, A Selective Il-23p19 Inhibitor, On Axial-Related Endpoints In Patients With Active Psa: Results From A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Through 2 Years

Mease, P.J., Helliwell, P., Gladman, D.D. et al. (10 more authors) (2022) POS1037 Effect Of Guselkumab, A Selective Il-23p19 Inhibitor, On Axial-Related Endpoints In Patients With Active Psa: Results From A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Through 2 Years. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 832-833.

Metadata

Authors/Creators:
  • Mease, P.J.
  • Helliwell, P.
  • Gladman, D.D.
  • Poddubnyy, D.
  • Baraliakos, X.
  • Chakravarty, S.D.
  • Kollmeier, A.
  • Xu, X.L.
  • Sheng, S.
  • Xu, S.
  • Shawi, M.
  • Van der Heijde, D.
  • Deodhar, A.
Dates:
  • Published (online): 23 May 2022
  • Published: 23 May 2022
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 22 Aug 2023 12:45
Last Modified: 22 Aug 2023 12:53
Published Version: http://dx.doi.org/10.1136/annrheumdis-2022-eular.1...
Status: Published
Publisher: BMJ
Identification Number: https://doi.org/10.1136/annrheumdis-2022-eular.1691
Related URLs:

Export

Statistics


CORE (COnnecting REpositories)